Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2024

Open Access 01-12-2024 | Methotrexate | Study protocol

The efficacy and safety of deucravacitinib compared to methotrexate, in patients with vulvar lichen planus who have failed topical therapy with potent corticosteroids: a study protocol for a single-centre double-blinded randomised controlled trial

Authors: Marlene Wijaya, Gayle Fischer, Rebecca Bronwyn Saunderson

Published in: Trials | Issue 1/2024

Login to get access

Abstract

Background

Vulvar lichen planus (VLP) is a chronic vulvar dermatosis that is difficult to treat and can severely impair quality of life in the absence of adequate treatment. There is a lack of high-quality evidence to direct therapy for VLP. This randomised controlled trial will be the first double-blinded study comparing systemic treatments in VLP and aims to investigate the safety and efficacy of deucravacitinib compared to methotrexate, in patients with VLP who have failed treatment with potent topical corticosteroids.

Methods

A total of 116 women aged ≥ 18 years with moderate to severe VLP (Genital Erosive Lichen Planus (GELP) score ≥ 5) will be recruited. All participants will initially be treated with Diprosone® OV daily, and their outcome will be assessed using the GELP score. At 8 weeks’ follow-up, responders (GELP < 5) will be continued on Diprosone® OV. Non-responders (GELP ≥ 5) will be randomised 1:1 in a blinded fashion to receive (i) methotrexate 10 mg weekly + placebo tablet twice daily + folic acid 5 mg weekly or (ii) deucravacitinib 6 mg twice daily + placebo tablet weekly + folic acid 5 mg weekly. The primary endpoint is the difference in the mean change of GELP scores from baseline to week 32 between deucravacitinib and methotrexate groups.

Discussion

High-quality evidence guiding the management of women with VLP is lacking. Once completed, this will be the first double-blinded RCT to compare systemic treatments in VLP. The results of this study will provide valuable, high-quality data to guide second-line therapy options for VLP that is recalcitrant to potent topical corticosteroids.

Trial registration

Australian New Zealand Clinical Trials Registry ACTRN12623000682640. Registered on 26 June 2023.
Literature
1.
Commonwealth Department of Community Services and Health. National Women’s Health Policy. Advancing Women’s Health in Australia. Canberra: Australian Government Publishing Service Canberra; 1989.
2.
Department of Health. National Women’s Health Strategy 2020–2030. Australia: Department of Health; 2018.
3.
Saunderson RB, Harris V, Yeh R, Mallitt KA, Fischer G. Vulvar quality of life index (VQLI) – a simple tool to measure quality of life in patients with vulvar disease. Australas J Dermatol. 2020;61(2):152–7.CrossRefPubMed
4.
Wu M, Kherlopian A, Wijaya M, Fischer G. Quality of life impact and treatment response in vulval disease: comparison of 3 common conditions using the Vulval Quality of Life Index. Australas J Dermatol. 2022;63(4):e320–8.CrossRefPubMedPubMedCentral
5.
Wijaya M, Lee G, Fischer G. Quality of life of women with untreated vulval lichen sclerosus assessed with vulval quality of life index (VQLI). Australas J Dermatol. 2021;62(2):177–82.CrossRefPubMed
6.
Wu M, Lee G, Fischer G. Forming diagnostic criteria for vulvar lichen planus. Australas J Dermatol. 2020;61(4):324–9.CrossRefPubMed
7.
Helgesen AL, Warloe T, Pripp AH, Kirschner R, Peng Q, Tanbo T, et al. Vulvovaginal photodynamic therapy vs. topical corticosteroids in genital erosive lichen planus: a randomized controlled trial. Br J Dermatol. 2015;173(5):1156–62.CrossRefPubMed
8.
Micheletti L, Preti M, Bogliatto F, Zanotto-Valentino MC, Ghiringhello B, Massobrio M. Vulval lichen planus in the practice of a vulval clinic. Br J Dermatol. 2000;143(6):1349–50.CrossRefPubMed
9.
Fahy CMR, Torgerson RR, Davis MDP. Lichen planus affecting the female genitalia: a retrospective review of patients at Mayo Clinic. J Am Acad Dermatol. 2017;77(6):1053–9.CrossRefPubMed
10.
Lundqvist E, Wahlin Y, Bergdahl M, Bergdahl J. Psychological health in patients with genital and oral erosive lichen planus. J Eur Acad Dermatol Venereol. 2006;20(6):661–6.CrossRefPubMed
11.
Cheng H, Oakley A, Conaglen JV, Conaglen HM. Quality of life and sexual distress in women with erosive vulvovaginal lichen planus. J Low Genit Tract Dis. 2017;21(2):145–9.CrossRefPubMed
12.
Helgesen AL, Gjersvik P, Jebsen P, Kirschner R, Tanbo T. Vaginal involvement in genital erosive lichen planus. Acta Obstet Gynecol Scand. 2010;89(7):966–70.CrossRefPubMed
13.
Kherlopian A, Fischer G. Vulvar malignancy in biopsy-proven vulval lichen planus: a retrospective review of 105 cases. Australas J Dermatol. 2020;61(4):386–8.CrossRefPubMed
14.
15.
Jang N, Fischer G. Treatment of erosive vulvovaginal lichen planus with methotrexate. Australas J Dermatol. 2008;49(4):216–9.CrossRefPubMed
16.
Deen K, McMeniman E. Mycophenolate mofetil in erosive genital lichen planus: a case and review of the literature. J Dermatol. 2015;42(3):311–4.CrossRefPubMed
17.
Vermeer HAB, Rashid H, Esajas MD, Oldhoff JM, Horvath B. The use of hydroxychloroquine as a systemic treatment in erosive lichen planus of the vulva and vagina. Br J Dermatol. 2021;185(1):201–3.CrossRefPubMedPubMedCentral
18.
Cooper SM, Wojnarowska F. Influence of treatment of erosive lichen planus of the vulva on its prognosis. Arch Dermatol. 2006;142(3):289–94.CrossRefPubMed
19.
Kherlopian A, Fischer G. Successful treatment of vulvovaginal lichen planus with tildrakizumab: a case series of 24 patients. Australas J Dermatol. 2022;63(2):251–5.CrossRefPubMed
20.
Skullerud KH, Gjersvik P, Pripp AH, Qvigstad E, Helgesen ALO. Apremilast for genital erosive lichen planus in women (the AP-GELP Study): study protocol for a randomised placebo-controlled clinical trial. Trials. 2021;22(1):469.CrossRefPubMedPubMedCentral
21.
Solimani F, Pollmann R, Schmidt T, Schmidt A, Zheng X, Savai R, et al. Therapeutic targeting of Th17/Tc17 cells leads to clinical improvement of lichen planus. Front Immunol. 2019;10:1808.CrossRefPubMedPubMedCentral
22.
Heelan K, McAleer MA, Roche L, McCreary C, Murphy M. Intractable erosive lichen planus treated successfully with rituximab. Br J Dermatol. 2015;172(2):538–40.CrossRefPubMed
23.
Tétu P, Monfort JB, Barbaud A, Francès C, Chasset F. Failure of rituximab in refractory erosive lichen planus. Br J Dermatol. 2018;179(4):980–1.CrossRefPubMed
24.
Chao TJ. Adalimumab in the management of cutaneous and oral lichen planus. Cutis. 2009;84(6):325–8.PubMed
25.
Sand FL, Thomsen SF. Off-label use of TNF-alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patients. Dermatol Ther. 2015;28(3):158–65.CrossRefPubMed
26.
Damsky W, Wang A, Olamiju B, Peterson D, Galan A, King B. Treatment of severe lichen planus with the JAK inhibitor tofacitinib. J Allergy Clin Immunol. 2020;145(6):1708-10 e2.CrossRefPubMed
27.
Dubey R, Fischer G. Vulvo-vaginal lichen planus: a focussed review for the clinician. Australas J Dermatol. 2019;60(1):7–11.CrossRefPubMed
28.
Kortekangas-Savolainen O, Kiilholma P. Treatment of vulvovaginal erosive and stenosing lichen planus by surgical dilatation and methotrexate. Acta Obstet Gynecol Scand. 2007;86(3):339–43.CrossRefPubMed
29.
Cline A, Cuellar-Barboza A, Jorizzo JL, Pichardo RO. Methotrexate for the treatment of recalcitrant erosive lichen planus of the vulva. JAMA Dermatol. 2020;156(2):215.CrossRefPubMedPubMedCentral
30.
Schwartz DM, Bonelli M, Gadina M, O’Shea JJ. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):25–36.CrossRefPubMed
31.
Armstrong AW, Gooderham M, Warren RB, Papp KA, Strober B, Thaci D, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88(1):29–39.CrossRefPubMed
32.
Mease PJ, Deodhar AA, Van Der Heijde D, Behrens F, Kivitz AJ, Neal J, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022;81(6):815–22.CrossRefPubMed
33.
Morand E, Pike M, Merrill JT, Van Vollenhoven R, Werth VP, Hobar C, et al. LB0004 efficacy and safety of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with active systemic lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study. Ann Rheum Dis. 2022;81(Suppl 1):209.CrossRef
34.
Strober B, Thaci D, Sofen H, Kircik L, Gordon KB, Foley P, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023;88(1):40–51.CrossRefPubMed
35.
Simpson RC, Thomas KS, Leighton P, Murphy R. Diagnostic criteria for erosive lichen planus affecting the vulva: an international electronic-Delphi consensus exercise. Br J Dermatol. 2013;169(2):337–43.CrossRefPubMedPubMedCentral
36.
Goldberg DP, Hillier VF. A scaled version of the General Health Questionnaire. Psychol Med. 1979;9(1):139–45.CrossRefPubMed
37.
Pascoe VL, Enamandram M, Corey KC, Cheng CE, Javorsky EJ, Sung SM, et al. Using the Physician Global Assessment in a clinical setting to measure and track patient outcomes. JAMA Dermatol. 2015;151(4):375.CrossRefPubMed
38.
StataCorp. Stata Statistical Software: Release 15. College Station: Stata Corp LLC; 2022.
39.
Cohen J. Statistical Power Analysis for the Behavioural Sciences. 2nd ed. Hillsdale: Lawrence Erlbaum Associates; 1998.
40.
Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. In: Services USDoHaH, editor. 2017.
41.
42.
Simpson RC, Murphy R, Bratton DJ, Sydes MR, Wilkes S, Nankervis H, et al. Help for future research: lessons learned in trial design, recruitment, and delivery from the “hELP” study. J Low Genit Tract Dis. 2018;22(4):405–8.CrossRefPubMedPubMedCentral
Metadata
Title
The efficacy and safety of deucravacitinib compared to methotrexate, in patients with vulvar lichen planus who have failed topical therapy with potent corticosteroids: a study protocol for a single-centre double-blinded randomised controlled trial
Authors
Marlene Wijaya
Gayle Fischer
Rebecca Bronwyn Saunderson
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Trials / Issue 1/2024
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-024-08022-y

Other articles of this Issue 1/2024

Trials 1/2024 Go to the issue

Study protocol

Zero Self-Harm app: a mobile phone application to reduce non-suicidal self-injury—study protocol for a randomized controlled trial

Study protocol

Sacral neuromodulation for constipation and fecal incontinence in children and adolescents – study protocol of a prospective, randomized trial on the application of invasive vs. non-invasive technique

Study protocol

IA-PACS-CFS: a double-blinded, randomized, sham-controlled, exploratory trial of immunoadsorption in patients with chronic fatigue syndrome (CFS) including patients with post-acute COVID-19 CFS (PACS-CFS)

Study protocol

Lifestyle intervention in children with obesity and nonalcoholic fatty liver disease (NAFLD): study protocol for a randomized controlled trial in Ningbo city (the SCIENT study)

Study protocol

Bent ab interno needle goniotomy versus gonioscopy-assisted transluminal trabeculotomy in primary open-angle glaucoma: study protocol of a randomized clinical trial

Study protocol

Efficacy of a 2-week therapy with levofloxacin concomitant versus a levofloxacin sequential regimen for Helicobacter pylori infection in the Syrian population: a study protocol for randomized controlled trial